scholarly journals A STUDY OF RISK FACTORS FOR RECURRENCE AND PREDICTIVE FACTORS FOR PROGNOSIS IN PATIENTS WITH STAGE II COLORECTAL CANCER

2010 ◽  
Vol 71 (9) ◽  
pp. 2227-2235
Author(s):  
Kiichi SUGIMOTO ◽  
Koichiro NIWA ◽  
Seigo ONO ◽  
Shun ISHIYAMA ◽  
Makoto TAKAHASHI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Predictive Factors ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer ◽  
Risk Factors For Recurrence

scholarly journals A STUDY OF RISK FACTORS FOR RECURRENCE IN STAGE II COLORECTAL CANCER

2010 ◽  
Vol 71 (3) ◽  
pp. 627-633 ◽  
Author(s):  
Tetsuo ISHIZAKI ◽  
Tetsuo SUMI ◽  
Yoshihiro YASUDA ◽  
Kenji KATSUMATA ◽  
Tatsuya AOKI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer ◽  
Risk Factors For Recurrence

scholarly journals Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence

Surgery Today ◽  
2013 ◽  
Vol 44 (5) ◽  
pp. 902-905 ◽  
Author(s):  
Takuzo Hashimoto ◽  
Michio Itabashi ◽  
Shinpei Ogawa ◽  
Tomoichiro Hirosawa ◽  
Yoshiko Bamba ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer ◽  
Risk Factors For Recurrence

Risk Factors For Recurrence In Postoperative Patients With Stage II Colorectal Cancer

2011 ◽  
Vol 165 (2) ◽  
pp. 337
Author(s):  
H. Ochiai ◽  
H. Hasegawa ◽  
Y. Ishii ◽  
T. Endo ◽  
T. Ohishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer ◽  
Risk Factors For Recurrence

scholarly journals Erratum to: Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence

Surgery Today ◽  
2014 ◽  
Vol 44 (9) ◽  
pp. 1791-1791
Author(s):  
Takuzo Hashimoto ◽  
Michio Itabashi ◽  
Shinpei Ogawa ◽  
Tomoichiro Hirosawa ◽  
Yoshiko Bamba ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer ◽  
Risk Factors For Recurrence

JCOG1805 (PanDRa-BD study): A randomized controlled study of adjuvant chemotherapy for stage II colorectal cancer patients at high-risk of developing recurrence according to T-stage and three selected pathological factors (Pn, DR, and BD).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS3621-TPS3621
Author(s):  
Megumi Ishiguro ◽  
Hideki Ueno ◽  
Atsuo Takashima ◽  
Junki Mizusawa ◽  
Keita Sasaki ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Multicenter Study ◽  
Prognostic Value ◽  
Stage Ii ◽  
Randomized Controlled ◽  
T Stage ◽  
Stage Ii Colorectal Cancer

TPS3621 Background: Adjuvant chemotherapy for stage II colorectal cancer (CRC) still remains controversial. Although the NCCN and ESMO guidelines recommend adjuvant chemotherapy for patients with “high-risk features,” the survival benefit has not been confirmed. We reviewed the evidence levels for prognostic values of risk factors, because lack of their robustness is a major source of uncertainty regarding the optimal indication of adjuvant chemotherapy. Consequently, on top of the T-stage, three pathological factors—perineural invasion (Pn), tumor budding (BD), and desmoplastic reaction (DR)—were selected as robust risk factors of recurrence. Among the conventional factors, the prognostic value of Pn had been well validated in a multicenter study conducted by the Japanese Society for Cancer of the Colon and Rectum (JSCCR; Am J Surg Path 2013), but others were deemed suboptimal in terms of the prognostic value. BD and DR are novel tumor- and stroma-factors, respectively, associated with cancer microenvironment at the tumor front. According to the JSCCR and ITBCC 2016 criteria, tumors are graded as BD1, BD2, or BD3. The DR heterogeneity is categorized into Mature, Intermediate, and Immature patterns based on site-specific products of cancer-associated fibroblasts—keloid-like collagen and myxoid stroma. According to a recent prospective multicenter study, BD and DR characterization represent a higher level of prognostic value than other conventional factors (SACURA trial; J Clin Oncol 2019, Br J Cancer 2021). Based on the four selected risk factors, we can exclude the patient group with favorable prognosis (i.e., > 90% of 5-year RFS), which accounts for approximately 40% of the total population, resulting in enabling us to identify the concentrated population of high risk of developing recurrence. Methods: The Japan Clinical Oncology Group (JCOG) launched a randomized controlled phase III trial to evaluate the superiority of adjuvant chemotherapy in terms of relapse-free survival (RFS) over observation only in stage II CRC patients aged 20–80 years having one or more of the following risk factors: pathological T4, Pn, BD3, and non-Mature DR. Patients are randomised, in a 1:1:1 ratio, to [A] observation, [B] capecitabine monotherapy for 6 months, or [C] capecitabine and oxaliplatin (CAPOX) for 3 months. A total of 1680 patients will be accrued from 54 Japanese institutions assuming 3-year RFS with [A] to be 82% and expected 5% increase in 3-year RFS for [B] and [C] with one-sided alpha of 2.5% and power of 80% for each pair comparison. Patient enrollment was started in January 2020 and 170 patients have been enrolled until January 2021. This trial has been registered at Japan Registry of Clinical Trials as jRCTs031190186. Clinical trial information: jRCTs031190186.

scholarly journals Recurrence risk factors in elderly patients with stage II colorectal cancer

2021 ◽  
Vol 29 (1) ◽  
pp. 5-10
Author(s):  
Akio Higuchi ◽  
Toru Aoyama ◽  
Yukari Takahashi ◽  
Norihiro Akimoto ◽  
Kohei Tsuchiya ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Elderly Patients ◽  
Recurrence Risk ◽  
Stage Ii ◽  
Stage Ii Colorectal Cancer

scholarly journals Lymph Node Morphology in Stage II Colorectal Cancer

2020 ◽  
Author(s):  
Annabelle Greenwood ◽  
John Keating ◽  
Diane Kenwright ◽  
Ali Shekouh ◽  
Alex Dalzell ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Lymph Node ◽  
Lymph Nodes ◽  
B Cell ◽  
Stage Ii ◽  
Cell Compartments ◽  
Stage Ii Colorectal Cancer ◽  
Draining Lymph Node ◽  
Draining Lymph Nodes

ABSTRACTBackgroundColorectal cancer is one of the leading causes of cancer-associated morbidity and mortality worldwide. The local anti-tumour immune response is particularly important for patients with stage II where the tumour-draining lymph nodes have not yet succumbed to tumour spread. The lymph nodes allow for the expansion and release of B cell compartments such as primary follicles and germinal centres. A variation in this anti-tumour immune response may influence the observed clinical heterogeneity in stage II patients.AimThe aim of this study was to explore tumour-draining lymph node histomorphological changes and tumour pathological risk factors including the immunomodulatory microRNA-21 (miR-21) in a small cohort of stage II CRC.MethodsA total of 23 stage II colorectal cancer patients were included. Tumour and normal mucosa samples were analysed for miR-21 expression levels and B-cell compartments were quantified from Haematoxylin and Eosin slides of lymph nodes. These measures were compared to clinicopathological risk factors such as perforation, bowel obstruction, T4 stage and high-grade.ResultsWe observed greater follicle density in patients with a lower tumour T stage and higher germinal centre density in patients with higher pre-operative carcinoembryonic antigen levels. Trends were also detected between tumours with deficiency in mismatch repair proteins, lymphatic invasion and both the density and size of B-cell compartments. Lastly, elevated tumour miR-21 was associated with decreased follicle and germinal centre size.ConclusionVariation in B-cell compartments of tumour-draining lymph nodes is associated with clinicopathological risk factors in stage II CRC patients.What does this paper add to the literature?This study demonstrates the variability of tumour draining lymph node morphological features in stage II CRC patients. This provides new scope for biomarker discovery in stage II CRC patients which is a research priority for this patient group.

Sign in / Sign up

Export Citation Format

Share Document